Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 2.13 | 2.29 | 2.08 | 19215 | 2.16343564 | CS |
| 4 | -0.21 | -8.97435897436 | 2.34 | 2.48 | 2.01 | 29747 | 2.1513058 | CS |
| 12 | -0.74 | -25.7839721254 | 2.87 | 4.1 | 1.72 | 518689 | 2.74125656 | CS |
| 26 | -0.1 | -4.48430493274 | 2.23 | 4.1 | 1.72 | 230111 | 2.73776971 | CS |
| 52 | -2.27 | -51.5909090909 | 4.4 | 10.6599 | 1.72 | 466399 | 6.04886605 | CS |
| 156 | -81.87 | -97.4642857143 | 84 | 102 | 1.72 | 278647 | 16.29407246 | CS |
| 260 | -162.87 | -98.7090909091 | 165 | 591.993 | 1.72 | 310400 | 99.01522234 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
